RecruitingPhase 2NCT07202598
Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
Studying Autoimmune polyendocrinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Michail S Lionakis, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Emapalumab(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 2-75 years · All sexes
- Timeline
- 2025 – 2031
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07202598 on ClinicalTrials.govOther trials for Autoimmune polyendocrinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07516886Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical ProstatectomyLithuanian University of Health Sciences
- RECRUITINGPHASE2NCT05398809Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT05578105Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in TaiwanNational Taiwan University Hospital